CD34

Across TCGA pan-cancer cohorts, CD34 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CD34’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CD34 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CD34 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LSCC are the cancer types where CD34 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD34 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−1.798	<.001	12	view →
COAD	Female	III,IV	−1.475	<.001	10	view →
LSCC	Male	All	−2.298	<.001	9	view →
LUAD	Female	II,III,IV	−1.682	<.001	9	view →
PDAC	All	II,III,IV	−0.356	.010	4	view →
OV	All	All	−2.765	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CD34–HNSC

Open the HNSC breakdown →